

Fingolimod patient, parent, caregiver guide

Important things for patients, parents and caregivers to remember about fingolimod treatment

If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

You can report side effects directly to the HPRA Pharmacovigilance via www.hpra.ie.
By reporting side effects, you can help provide more information on the safety of this medicine.


All pregnancies and side effects may also be reported to Flynn Pharma Limited Medical Information via medinfo@flynnpharma.com or +44 (0) 1438 727822.

This material fulfils the conditions of the marketing authorization and has been approved by the HPRA. Please see the patient information leaflet for more information available at www.hpra.ie

What is multiple sclerosis (MS)?

MS is a long-term autoimmune condition that affects the central nervous system (CNS), comprised of the brain and spinal cord. In MS, the inflammation destroys the protective sheath (called myelin) around the nerves in the CNS and stops the brain cells (neurons) from working properly. This is called demyelination.


Relapsing-remitting MS is characterised by repeated attacks (relapses) that reflect inflammation within the CNS. Symptoms vary from patient to patient. Symptoms of a relapse may disappear completely when the relapse is over, but some problems may remain.



How does fingolimod work?

Your immune system normally fights infections to prevent illnesses. However, if you have MS it can become overactive and attack the myelin that protect the neurons and help them to carry messages from your brain to the rest of your body.

Fingolimod helps to protect against attacks on the CNS by the immune system by reducing the ability of some white blood cells (lymphocytes) to move freely within the body and by stopping them from reaching the brain and spinal cord. This can reduce the neural damage caused by MS.



Contraindications and precautions

The doctor will ask the person who has been prescribed fingolimod, to stay at the clinic for 6 hours or more after taking the first dose so that appropriate measures can be taken if side effects occur. In some circumstances, an overnight stay may be required. For paediatric patients similar precautions will be taken if their dose is increased from 0.25 mg to 0.5 mg once daily.

Fingolimod should not be used in patients with specific cardiac diseases, and is not recommended in patients who are also taking medicines that are known to decrease heart rate.

Fingolimod should not be used in women who are pregnant or in women of child-bearing potential (including female adolescents) if they are not using effective contraception.

If you are a woman of child-bearing potential or the parent/caregiver of a female adolescent of child-bearing potential prescribed fingolimod, you will be provided with a Pregnancy-Specific Patient Reminder Card.

Please read the Patient Information Leaflet thoroughly before you or the child/adolescent in your care starts treatment with fingolimod. You should keep the Patient Information Leaflet in case you need to refer to it during your treatment. Please inform your doctor if the individual taking fingolimod or a family member, has a history of epilepsy.

Contact your doctor immediately if you or the child/adolescent in your care experiences any adverse reactions during treatment with fingolimod. Any doctors that you or the child/adolescent in your care sees should be told they are taking fingolimod.

Before starting fingolimod treatment

Pregnancy

Fingolimod can harm an unborn baby (the medicine is said to be 'teratogenic'). Women of child-bearing potential (including female adolescents) should be informed by their doctor about fingolimod's serious risk to the unborn baby. Women of child-bearing potential (including female adolescents) must have a negative pregnancy test and be using effective contraception before starting treatment with fingolimod.

Human papilloma virus (HPV)-related cancer

Your doctor will assess whether you need to undergo cancer screening (including a Pap test) and if you should receive the HPV vaccine.

Liver function

Fingolimod can cause abnormal results in liver function tests. You or the child/adolescent in your care, will need a blood test prior to treatment initiation with fingolimod.

The first time you take fingolimod

Slow heart rate and irregular heartbeat

At the beginning of treatment, fingolimod causes the heart rate to slow down. This may make you feel dizzy or lower your blood pressure. If you or the child/adolescent in your care, experiences symptoms such as dizziness, nausea, vertigo, or palpitations or feel uncomfortable after taking the first dose of fingolimod, please immediately inform your doctor.

Before you take the first dose, you or the child/adolescent will have:

- A baseline electrocardiogram (ECG) to assess the action of their heart
- A blood pressure measurement
- Children will also be weighed and measured, and will undergo a physical development assessment.

During the 6-hour monitoring:

- Pulse and blood pressure is checked every hour
 - You or the child/adolescent may be monitored with a continuous ECG during this time
- An ECG at the end of 6 hours

It is important to ensure medication compliance and avoid misuse especially treatment interruption which may result in a requirement to repeat cardiac monitoring. Call the doctor in case of treatment interruption if you or the child/adolescent has stopped fingolimod for at least:

- 1 day or more during first 2 weeks of treatment
- Or more than 7 days during weeks 3 and 4 of treatment
- Or more than 2 weeks after one month on treatment

as the initial effect on your heart rate may occur again. When fingolimod therapy is restarted, the doctor may decide to repeat monitoring of heart rate and blood pressure measurements every hour, to run ECGs, and if needed, to monitor you or the child/adolescent overnight.

While you are taking fingolimod

Infections

Because fingolimod affects the immune system, you are more likely to get infections. If you think you have any of the following, during and up to 2 months after stopping treatment, seek urgent medical attention: a headache accompanied by a stiff neck, sensitivity to light, fever, flu-like symptoms, nausea, rash, shingles and/or confusion or seizures (fits) (these may be symptoms of meningitis and/or encephalitis, either caused by fungal or viral infection).

If you believe your MS or that of the child/adolescent in your care is getting worse (e.g. confusion, changes in mood or behaviour, memory lapses, speech and communication difficulties, new or worsening weakness on one side of the body or changes in vision) or if you notice any new symptoms, talk to your doctor as soon as possible.

These may be the symptoms of a rare brain disorder called progressive multifocal leukoencephalopathy (PML) which is caused by an infection that may lead to severe disability or death. PML can be treated and treatment with Fingolimod will be stopped.

Some people get an inflammatory reaction as Fingolimod is removed from the body. This inflammatory reaction called immune reconstitution inflammatory syndrome (IRIS), may lead to worsening of your condition including worsening brain function.

Your doctor will arrange magnetic resonance imaging (MRI) scans before you start treatment and during treatment to monitor the risk of PML. You should also speak with your partner or caregivers and inform them about your treatment. Symptoms might arise that you might not become aware of by yourself.

Cancer

The doctor will assess whether any individuals taking fingolimod needs to undergo cancer screening (including a Pap test), and if they should receive the human papilloma virus (HPV) vaccine.

Skin cancer

Skin cancers have been reported in multiple sclerosis patients treated with fingolimod. Inform your doctor immediately if you notice any skin nodules (e.g. shiny, pearly nodules), patches or open sores that do not heal within weeks. Symptoms of skin cancer may include abnormal growth or changes of skin tissue (e.g. unusual moles) with a change in colour, shape or size over time.

Liver function

Some cases of acute liver failure requiring liver transplant and clinically significant liver injury have been reported. A blood test to assess liver function is required before starting treatment with fingolimod and at months 1,3,6,9 and 12. Regular liver function tests are also required until 2 months after fingolimod discontinuation.

Inform the doctor if you notice any yellowing of the skin or the whites of the eyes, abnormally dark urine, pain on the right side of the stomach area, tiredness, feeling less hungry than usual or unexplained nausea and vomiting as these can be signs of liver injury.

Pregnancy

Women of child-bearing potential (including female adolescents) should be provided with regular counselling about fingolimod's serious risks to an unborn baby by their doctor.

Women of child-bearing potential (including female adolescents) must have a negative pregnancy test before starting treatment with fingolimod and must use effective contraception while taking fingolimod and for two months after stopping treatment, because of the serious risks of fingolimod to the unborn baby.

In case of pregnancy (intended or unintended) during treatment, or in the 2 months after stopping treatment with fingolimod, the doctor should be informed straight away.

Visual symptoms

Fingolimod may cause swelling at the back of the eye, a condition that is known as macular oedema. Contact the doctor immediately if you or the child/adolescent in your care experience visual symptoms during and up to 2 months after stopping treatment.

Depression and anxiety

Depression and anxiety have been reported in paediatric patients treated with fingolimod. Talk to your doctor if you or the child/adolescents in your care are experiencing symptoms.

Stopping fingolimod

Stopping fingolimod therapy may result in return of disease activity. Your doctor will decide whether and how you need to be monitored after stopping fingolimod.

Reporting of side effects

If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

You can report side effects directly to the HPRA Pharmacovigilance via www.hpra.ie.

By reporting side effects, you can help provide more information on the safety of this medicine.

All pregnancies and side effects may also be reported to Flynn Pharma Limited Medical Information via medinfo@flynnpharma.com or +44 (0) 1438 727822.